Trials / Completed
CompletedNCT04513665
ZW25 in Women With Endometrial Cancers
A Phase 2 Trial of ZW25 in HER2 Overexpressed Advanced Endometrial Cancers and Carcinosarcomas (ZW25-IST-2)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to test the drug ZW25 and look at whether this drug is effective in women with HER2-overexpressed endometrial cancer or carcinosarcoma that has been treated in the past.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZW25 | ZW25 at 20mg/kg intravenously (IV) every two weeks. |
Timeline
- Start date
- 2020-08-12
- Primary completion
- 2024-03-08
- Completion
- 2024-03-08
- First posted
- 2020-08-14
- Last updated
- 2025-05-22
- Results posted
- 2024-10-21
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04513665. Inclusion in this directory is not an endorsement.